1999
Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit.
Marks MJ, Whiteaker P, Calcaterra J, Stitzel JA, Bullock AE, Grady SR, Picciotto MR, Changeux JP, Collins AC. Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit. Journal Of Pharmacology And Experimental Therapeutics 1999, 289: 1090-103. PMID: 10215692.Peer-Reviewed Original ResearchConceptsBeta2 subunitBeta2 null mutant miceConcentration-effect curvesMouse brain synaptosomesAlpha4beta2 receptorsBrain synaptosomesNicotinic agonistsMouse brainRubidium effluxMutant miceLine radioactivity detectionDHbetaEAgonistsEffluxBrainStimulationRadioactivity detectionPotencyHexamethoniumErythroidineResponseAcetylcholineMethyllycaconitineAntagonistBungarotoxin
1998
Pharmacological characterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes.
Lu Y, Grady S, Marks M, Picciotto M, Changeux J, Collins A. Pharmacological characterization of nicotinic receptor-stimulated GABA release from mouse brain synaptosomes. Journal Of Pharmacology And Experimental Therapeutics 1998, 287: 648-57. PMID: 9808692.Peer-Reviewed Original ResearchConceptsGamma-aminobutyric acidGABA releaseMouse brain synaptosomesBrain synaptosomesNicotinic agonistsNicotine bindingBeta2 null mutant miceNull mutant miceRecent electrophysiological studiesRodent brain tissueConcentration-dependent mannerAgonist inhibitionAlpha-BungarotoxinNeurochemical approachesPharmacological characterizationNM tetrodotoxinElectrophysiological studiesSame agonistBrain regionsBrain tissueMutant miceAgonistsEmax valuesBeta2 subunitMaximal release